Topic: cardiovascular disease
Jazz Pharmaceuticals’ narcolepsy drug bested placebo at keeping patients awake during the day and tamping down on cataplexy attacks, or sudden paralysis.
Sanifit is breaking the mold in its native country: Back in June, it raised a massive €55.2 million ($62.9 million) series D round, smashing Spanish biotech VC records and ranking as one of the biggest life sciences raises in Europe for the year.
Launched in February with $250 million and a midphase heart disease drug from Novartis, Anthos’ sizable war chest means it can run large cardiovascular studies that are often beyond the reach of young biotech companies.
Philips is adding LindaCare’s remote monitoring platform for patients with cardiac implants to its IntelliSpace Cardiovascular informatics program.
Medicines Company is yet to share the efficacy data that will show whether inclisiran can compete but has sought to tackle lingering safety concerns.
Reinhardt, who helped GlaxoSmithKline get a gene therapy to market, joins XyloCor to advance genetic treatments for cardiovascular diseases.
Bayer tapped Sensyne Health to sift through patient data from the NHS and apply the findings to its cardiovascular disease pipeline.
Scientists at Boston Children's Hospital have created a gene therapy technique that suppressed heart arrhythmias in mice.
Understanding aging in cells beyond the brain could lead to new therapies for diabetes and more, Salk scientists say.
The partners will apply Arvinas’ targeted protein degrader technology to cardiovascular, oncological and gynecological targets selected by Bayer.